Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TORCH-OPTIMA: Neoadjuvant Immunotherapy +/- Radiotherapy in Locally Advanced MSI-H/dMMR Colorectal Cancer
NCT07403877Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Feb 2026
- Primary completion
- Dec 2031
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in colorectal cancer (CRC), sponsored by Fudan University. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07403877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07403877.